CD24 and breast cancer: To evaluate the effect of Gomisin M2 on BCSCs, we first analyzed the activity of Gomisin M2 against the breast cancer stem cells (with the CD44+/CD24- biomarkers) in MDA-MB-231 and HCC1806 cells.